Pulmonary arterial hypertension associated with another diseaseNews & Research
14 curated articles for Pulmonary arterial hypertension associated with another disease — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- PharmacoEconomics May 5, 2026
Application of a Prevalence-Adjusted Cost-Effectiveness Threshold Framework for Pulmonary Arterial Hypertension.
Pulmonary arterial hypertension (PAH) is a rare, progressive condition associated with high per-patient treatment costs and substantial clinical burden. Interpreting cost-effectiveness evidence for rare diseases remains challenging when uniform thresholds are applied across conditions that differ ma...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension associated with another disease that may be relevant for patients and caregivers.
- Clinica chimica acta; international journal of clinical chemistry Apr 28, 2026
Right ventricular-centered metabolomics: A promising tool for phenotyping pulmonary arterial hypertension.
Recent advances in plasma metabolomics have highlighted the potential role of right ventricular-centered metabolic profiling in pulmonary arterial hypertension associated with atrial septal defect. By commenting on a trans-cardiac metabolomic gradient approach, this letter discusses how right ventri...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension associated with another disease that may be relevant for patients and caregivers.
- PloS one Apr 28, 2026
Economic burden of pulmonary arterial hypertension in Switzerland.
Pulmonary arterial hypertension (PAH) is a rare, progressive condition associated with high morbidity and healthcare resource utilization. This study aimed to estimate the annual direct and indirect costs of PAH in Switzerland, from a societal perspective. A cross-sectional cost-of-illness study was...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension associated with another disease that may be relevant for patients and caregivers.
- The Journal of pediatrics Apr 15, 2026
Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial.
To evaluate pharmacokinetics (PK), efficacy, and safety of macitentan vs standard of care (SoC) in pediatric pulmonary arterial hypertension (PAH). TOMORROW was a multicenter, open-label, phase 3 clinical trial in patients aged ≥2-<18 years World Health Organization Functional Class I-III....
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension associated with another disease that may be relevant for patients and caregivers.
- Comprehensive Physiology Apr 1, 2026
The Importance of Liver-Lung Communication in Pulmonary Vascular Diseases.
In normal health, the liver and lungs enjoy a close anatomic, physiologic, and functional relationship. In the context of pulmonary vascular disease, however, there is accumulating evidence that the interplay between the gut microbiome, hepatic system, and pulmonary vasculature (so-called "gut-liver...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension associated with another disease that may be relevant for patients and caregivers.
- Expert review of respiratory medicine Mar 30, 2026
Daytime sleepiness in patients with obstructive sleep apnea and associated comorbidities.
Obstructive sleep apnea (OSA) is characterized by recurrent upper-airway collapse during sleep, leading to ineffective respiratory efforts, intermittent hypoxia, and sleep fragmentation. Patients with OSA often have comorbid conditions. Excessive daytime sleepiness (EDS), defined as an inability to ...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension associated with another disease that may be relevant for patients and caregivers.
- Pulmonary circulation Mar 12, 2026
Sotatercept in Patients With Eisenmenger Syndrome.
Eisenmenger syndrome represents a complex and severe form of pulmonary arterial hypertension (PAH) associated with congenital heart disease. Sotatercept, a first-in-class activin-signaling inhibitor, offers a novel therapeutic approach in the treatment of PAH, and has emerged as a promising therapeu...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension associated with another disease that may be relevant for patients and caregivers.
- European journal of heart failure Mar 9, 2026
Risk stratification for adult patients with pulmonary arterial hypertension associated with congenital heart disease. A scientific statement of the ESC Working Group on Pulmonary Circulation & Right Ventricular Function, the ESC Working Group on Adult Congenital Heart Disease, and the Association of Cardiovascular Nursing & Allied Professions of the ESC.
For patients with pulmonary arterial hypertension (PAH), current guidelines recommend a 3- and 4-strata risk stratification model at baseline and follow-up, respectively. Risk stratification models in PAH are mainly derived from idiopathic PAH cohorts and are not automatically applicable to all pati...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension associated with another disease that may be relevant for patients and caregivers.
- Vascular pharmacology Mar 9, 2026
ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of REVEAL risk score.
Our understanding of pulmonary arterial hypertension (PAH) pathophysiology and treatment has significantly improved over time. Within this scenario we established the Italian Network on Pulmonary Arterial Hypertension (IPHNET), promoting a national prospective registry (ASPYRE-1) to collect data on ...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension associated with another disease that may be relevant for patients and caregivers.
- Expert review of respiratory medicine Mar 6, 2026
Rituximab treatment for connective tissue diseases associated-pulmonary hypertension: a systematic literature review.
To evaluate the efficacy and safety of Rituximab (RTX) in the treatment of pulmonary hypertension (PH) in patients with connective tissue diseases (CTDs). A systematic review of the published literature was performed according to the PRISMA guidelines. Eligible articles were clinical trials, cohort ...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension associated with another disease that may be relevant for patients and caregivers.
- European respiratory review : an official journal of the European Respiratory Society Feb 18, 2026
Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons.
Pulmonary arterial hypertension (PAH) is a severe disease characterised by a progressive thickening and obliteration of pulmonary vessels, resulting in increased vascular resistance, elevated pulmonary artery pressures, and right heart failure. Among the various conditions associated with PAH, syste...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension associated with another disease that may be relevant for patients and caregivers.
- Cardiovascular research Feb 14, 2026
Remodelling of the endothelial extracellular matrix promotes smooth muscle cell hyperplasia in pulmonary hypertension due to left heart disease.
Hyperplasia of pulmonary arterial smooth muscle cells (SMCs) contributes to the progression of pulmonary hypertension (PH), yet the underlying pathomechanism of this process in PH secondary to left heart disease (PH-LHD) is poorly understood. We aimed to investigate the role of the endothelial extra...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension associated with another disease that may be relevant for patients and caregivers.
- Clinical pharmacology and therapeutics Feb 7, 2026
Respiratory Disorders Associated with Antibody-Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases.
Antibody-drug conjugates are proving to be highly effective in oncology, yet their real-world respiratory safety profile remains largely unknown. This study sought to characterize drug-linked respiratory disorders and identify safety signals. We performed a descriptive analysis with expert review of...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension associated with another disease that may be relevant for patients and caregivers.
- Free radical biology & medicine Feb 7, 2026
TRAF6 mediates vascular remodeling via endoplasmic reticulum stress-mitophagy in hypoxic pulmonary hypertension.
Hypoxia-induced pulmonary hypertension (HPH) is a cardiopulmonary disease marked by pulmonary vascular remodeling and elevated resistance in the pulmonary arteries. Tumor necrosis factor receptor-associated factor 6 (TRAF6) is a key mediator in the pathophysiology of multiple diseases, yet its funct...
Why it matters: Recent peer-reviewed research on Pulmonary arterial hypertension associated with another disease that may be relevant for patients and caregivers.
More on Pulmonary arterial hypertension associated with another disease
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.